{"title": "The Globe and Mail", "author": null, "url": "https://www.theglobeandmail.com/investing/markets/markets-news/PR%20Newswire/17432361/innovent-updates-phase-1b-data-of-ibi939-anti-tigit-monoclonal-antibody-combined-with-sintilimab-in-previously-untreated-pd-l1-selected-nsclc-at-the-2023-asco-annual-meeting/", "hostname": "theglobeandmail.com", "description": "PR Newswire Press Release.", "sitename": "The Globe and Mail", "date": "2023-06-03", "cleaned_text": "Innovent Biologics, Inc. (\"Innovent\") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, updated the Phase 1b efficacy and safety results of IBI939 (anti-TIGIT antibody) combined with sintilimab (anti-PD-1 antibody) in previously untreated PD-L1-selected NSCLC without sensitizing mutations at the 2023 American Society of Clinical Oncology (ASCO) Annual "}